Requirement for IL-13 independently of IL-4 in experimental asthma - PubMed (original) (raw)

Requirement for IL-13 independently of IL-4 in experimental asthma

G Grünig et al. Science. 1998.

Abstract

The pathogenesis of asthma reflects, in part, the activity of T cell cytokines. Murine models support participation of interleukin-4 (IL-4) and the IL-4 receptor in asthma. Selective neutralization of IL-13, a cytokine related to IL-4 that also binds to the alpha chain of the IL-4 receptor, ameliorated the asthma phenotype, including airway hyperresponsiveness, eosinophil recruitment, and mucus overproduction. Administration of either IL-13 or IL-4 conferred an asthma-like phenotype to nonimmunized T cell-deficient mice by an IL-4 receptor alpha chain-dependent pathway. This pathway may underlie the genetic associations of asthma with both the human 5q31 locus and the IL-4 receptor.

PubMed Disclaimer

Figures

Fig. 1

Fig. 1

PAS-stained histologic sections of murine lungs. Arrowheads point to goblet cells within the respiratory epithelium. (A) Wild-type mice were primed with OVA and challenged with PBS intranasally. (B) Wild-type mice were administered IL-13 intranasally. (C) IL-4–deficient and (D) IL-4Rα–deficient mice were primed with OVA and challenged with OVA intranasally. Wild-type mice were primed with OVA and challenged intranasally with (E) OVA and human Fc control protein or with (F) OVA and IL-13R-Fc. Note the marked reduction in goblet cells in (D) and (F).

Fig. 2

Fig. 2

Effect of neutralization of IL-13. Primed wild-type mice were administered intranasally human immunoglobulin (Ig control), Ig control and OVA, or IL-13R-Fc and OVA as indicated by (+). Data for (A) AHR, (B) goblet cell score, and numbers of (C) eosinophils and (D) neutrophils in the BAL fluid are plotted as means ± SEM. *P < 0.05 relative to PBS and Ig control–treated mice; †P < 0.05 relative to OVA and Ig control–treated mice. Data are representative of at least two comparable experiments with four to eight mice per group.

Fig. 3

Fig. 3

Effect of recombinant IL-4 and IL-13. Wild-type (WT), RAG1-deficient (RAG1−/−), and IL-4Rα–deficient (IL-4Rα−/−) mice were administered IL-4, IL-13, or control protein intranasally. Data for (A) AHR, (B) goblet cell score, and numbers of (C) eosinophils and (D) neutrophils in the BAL fluid are plotted as means ± SEM. *P < 0.05 relative to mice receiving control protein. Data are representative of at least two comparable experiments with four to eight mice per group.

Comment in

Similar articles

Cited by

References

    1. Molfino NA, Nannini LJ, Martelli AN, Slutsky AS. N. Engl. J. Med. 1991;324:285. - PubMed
    1. Goldstein RA, Paul WE, Metcalfe DD, Busse WW, Reece ER. Ann. Intern. Med. 1994;121:698. - PubMed
    1. Gavett SH, Chen X, Finkelman F, Wills-Karp M. Am. J. Respir. Cell Mol. Biol. 1994;10:587. - PubMed
    1. Watanabe A, et al. ibid. 1997;16:69. - PubMed
    2. Garssen J, Nijkamp FP, Van Der Vliet H, Van Loveren H. Am. Rev. Respir. Dis. 1991;144:931. - PubMed
    3. Rankin JA, et al. Proc. Natl. Acad. Sci. U.S.A. 1996;93:7821. - PubMed
    4. Foster PS, Hogan SP, Ramsay AJ, Matthaei KI, Young IG. J. Exp. Med. 1996;183:195. - PMC - PubMed
    5. Mauser PJ, et al. Am. Rev. Respir. Dis. 1993;148:1623. - PubMed
    1. Brusselle G, Kips J, Joos G, Bluethmann H, Pauwels R. Am. J. Respir. Cell Mol. Biol. 1995;12:254. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources